ORIENTAL-MeVO — Endovascular Treatment of Medium-Vessel-Occlusion Strokes

1. Publication

• Title: Endovascular Treatment of Medium-Vessel-Occlusion Strokes
• Acronym: ORIENTAL-MeVO
• Year & Journal: New England Journal of Medicine, 2026;394(19)
• Citation: Hu W, Jing X, Chen Z, et al. Endovascular Treatment of Medium-Vessel-Occlusion Strokes. N Engl J Med. 2026. doi:10.1056/NEJMoa2514120

2. Context & Rationale

Background: Endovascular thrombectomy (EVT) is highly effective for large-vessel-occlusion (LVO) stroke, per HERMES Collaboration meta-analysis. Whether this benefit extends to medium-vessel occlusion (MeVO) — e.g., M2/M3 MCA segments, A2/A3 ACA, P1/P2 PCA — had shown varying results across prior trials, and remained unclear specifically for patients with moderate-to-severe deficits.

Research Question/Hypothesis: In patients with acute ischemic stroke due to MeVO and moderate-to-severe deficits (NIHSS ≥6), presenting within 24 hours, does EVT plus medical management improve functional outcomes compared with medical management alone?

Why This Matters: MeVO strokes are common but a substantial proportion of patients fail to achieve favorable outcomes with best medical treatment alone; whether the large LVO-EVT effect size generalizes to this population had direct implications for expanding thrombectomy eligibility.

3. Design & Methods

• Study Type: Open-label, randomized trial with blinded outcome assessment
• Setting & Centers: 48 centers, China; conducted 2023–2025
• Population:
• Inclusion: Adults presenting within 24h of onset of moderate-to-severe stroke (NIHSS ≥6) due to medium-vessel occlusion
• Exclusions: Patients with large infarctions (per imaging criteria)
• Intervention: Endovascular thrombectomy plus medical management
• Comparator: Medical management alone
• Randomization: 1:1, 564 adults (281 thrombectomy, 283 control); median age 71y, 43% female
• Blinding: Open-label treatment; blinded outcome assessment
• Statistical Power & Follow-Up: Primary outcome: functional disability via shift in mRS at 90 days. Functional independence assessed via telephone interviews/caregiver reports (acknowledged possible misclassification bias).

4. Key Results

5. Internal Validity Assessment

• Randomization & Allocation: 1:1 randomization across 48 centers; specific concealment mechanics not detailed in available trial text.
• Protocol Adherence & Separation: Device-based intervention (EVT) inherently delivers strong procedural separation from medical management alone.
• Blinding & Detection Bias: Open-label treatment (unavoidable for a procedural intervention) but blinded outcome assessment — meaningfully reduces detection bias. However, functional independence was determined via telephone interviews and patient/caregiver reports, introducing a specific, acknowledged misclassification-bias risk distinct from treatment-blinding concerns.
• Missing Data & Sensitivity Analyses: Not detailed in available trial text.
• Overall Internal Validity Conclusion: Moderate-to-good — blinded outcome assessment and a robust effect size (RR 1.24, P=0.004) support the primary finding, but the telephone/caregiver-report-based outcome ascertainment method is a genuine, self-acknowledged limitation for a study of this size and importance.

6. External Validity Assessment

• Population Representativeness: Chinese population, moderate-to-severe MeVO stroke (NIHSS ≥6), median age 71y — patients with large infarctions were excluded by imaging criteria, which may limit generalizability to the full MeVO spectrum.
• Practice Context: Requires EVT capability and expertise for smaller/more distal vessel occlusions than typical LVO thrombectomy — a technically more demanding procedure, with resource and training implications for broader adoption.
• Overall External Validity Conclusion: Moderate-to-good for Chinese and similar health systems with EVT capability extending to medium-vessel occlusions; imaging-based exclusion of large infarctions somewhat narrows the population to whom results directly apply.

7. Strengths & Limitations

Strengths:

• Addresses a genuine, clinically important gap (does LVO's EVT benefit generalize to MeVO with moderate-to-severe deficits)
• Blinded outcome assessment strengthens an open-label procedural trial
• Clear, statistically robust primary result (NNT~8) without mortality difference
• Adds to and helps resolve inconsistency across prior MeVO thrombectomy trials

Limitations:

• Higher rate of (at least any, possibly symptomatic per some reporting) intracranial hemorrhage with thrombectomy — a genuine safety tradeoff
• Functional independence ascertainment via telephone/caregiver report introduces misclassification-bias risk
• Exclusion of large infarctions by imaging criteria limits generalizability to the full MeVO population
• Single-country (China) trial

8. Interpretation & Practice Impact

• Clinical Implications: Supports EVT for MeVO stroke specifically in patients with moderate-to-severe deficits (NIHSS ≥6), extending thrombectomy's established LVO benefit to this population, while requiring careful patient selection to balance the hemorrhage risk against functional benefit.
• Mechanistic Coherence: Consistent with the general principle that vessel recanalization improves outcomes in ischemic stroke, extending this to more distal/smaller-caliber occlusions than classic LVO trials tested.
• Systems-Level Takeaway: Per the accompanying NEJM editorial ("Narrowing the Target Population"), the field's focus is shifting toward identifying which specific MeVO patients benefit most, given the added technical complexity and hemorrhage risk relative to standard LVO thrombectomy.

9. Controversies & Subsequent Evidence

• Editorial Commentary: The accompanying NEJM editorial by Ospel and Hill explicitly frames the key ongoing question as "narrowing the target population" for MeVO thrombectomy — i.e., not whether EVT can work in MeVO (this trial and others suggest it can), but which specific MeVO patients benefit enough to justify the added procedural risk.
• Guideline Integration: Contributes to a broader, evolving MeVO thrombectomy evidence base alongside other recent trials (e.g., DISTAL, which found EVT increased functional independence without significant mortality/symptomatic-ICH differences, though any-ICH was more frequent with EVT) — collectively suggesting the optimal reperfusion strategy for MeVO remains dependent on patient selection, occlusion characteristics, and procedural factors rather than being a uniformly "yes" or "no" answer.

10. Summary & Executive Takeaway

Summary: This Chinese multicenter trial randomized 564 patients with MeVO stroke and moderate-to-severe deficits (NIHSS ≥6) to EVT plus medical management or medical management alone. Functional independence at 90 days was significantly higher with thrombectomy (58.6% vs 46.6%; adjusted RR 1.24, 95% CI 1.07–1.44, P=0.004; NNT~8), with a higher rate of intracranial hemorrhage but no mortality difference.

Overall Takeaway: EVT extends its established LVO benefit to medium-vessel-occlusion stroke with moderate-to-severe deficits, meaningfully improving functional independence — but with a real hemorrhage-risk tradeoff that argues for careful, selective application rather than blanket extension of thrombectomy criteria to all MeVO strokes.

11. Bibliography

• Ospel JM, Hill MD. Endovascular Therapy for Medium-Vessel Occlusion Stroke — Narrowing the Target Population [editorial]. N Engl J Med. 2026;394(19):1955-1957.
• Fischer U, et al. Endovascular treatment for medium or distal vessel occlusion stroke (DISTAL): 12-month outcomes. Lancet Neurol. 2026;25(6):571-580.